Levetiracetam Rudipharm (Levetiracetam)

Levetiracetam binds to the synaptic vesicle protein SV2A, which regulates neurotransmitter release. This binding modulates synaptic activity, reduces excessive neuronal firing, and lowers the likelihood of seizure initiation and propagation throughout the central nervous system.

The dosage of Levetiracetam Rudipharm is individualized by the prescribing clinician based on the patient’s age, weight, renal function, and seizure type. Only a qualified healthcare professional should determine the appropriate dose and titration schedule.

Safety data for levetiracetam in pregnancy and lactation are limited. Clinicians must weigh the potential benefits of seizure control against any possible risks to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss treatment options with their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Levetiracetam offers a distinct mechanism by targeting SV2A, which differs from sodium‑channel blockers like carbamazepine or GABA‑enhancers such as valproate. It is generally well tolerated, has fewer drug‑enzyme interactions, and can be combined with many other antiepileptics, making it a versatile option in seizure management.

Levetiracetam Rudipharm tablets should be stored at ambient temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from moisture and direct sunlight, and ensure the container is tightly closed to maintain stability.

Levetiracetam Rudipharm is taken orally, usually with or without food. Tablets are swallowed whole with a glass of water. The exact dosing schedule—once daily, twice daily, or more—depends on the prescriber’s assessment of the patient’s clinical needs.

Serious risks include severe allergic reactions (e.g., rash, swelling, breathing difficulty), significant mood or behavioral changes such as depression or suicidal thoughts, and rare hematologic or hepatic abnormalities. Patients should be monitored closely for any of these events and seek immediate medical attention if they occur.

Levetiracetam is contraindicated in individuals with known hypersensitivity to levetiracetam or any of its excipients. Caution is also advised for patients with severe renal impairment who may require dose adjustment, and for those with a history of serious psychiatric disorders without appropriate monitoring.